LENZ Therapeutics, Inc. (LENZ) fair value analysis
Nasdaq · Updated 2026-10-19
LENZ price how computed
Valuation status
No fair-value estimate yetLENZ has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for LENZ yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $3.27
- Sector
- Healthcare
- 12-month range
- $3.27–$31.97
- Market cap
- $103M
- From 52-week high
- -89.8%
- Shares outstanding
- 31.4M
- Rank in Healthcare by quality score
- #190 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for patients with retinal diseases and other serious eye conditions. The company is based in the United States and operates within the broader healthcare sector.
LENZ currently ranks #190 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $103M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $21.5M
- Net margin
- -586.7%
- EPS (TTM)
- $-4.09
- Gross margin
- 94.9%
- Debt / equity
- 0.00
- Shares outstanding
- 31.4M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 32 · neutral
- 50-day average
- $4.41
- 200-day average
- $8.67
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2024-03-15)
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+15.7%)
2026-03 ▼ miss (-23.3%)
2025-12 ▼ miss (-26.1%)
2025-09 ▲ beat (+11.9%)
2025-06 ▲ beat (+1.9%)
2025-03 ▼ miss (-65.6%)
2024-12 ▼ miss (-9.5%)
2024-09 ▲ beat (+11.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 2 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $23.9
- Target vs last price
- +630.9%
What our data shows for LENZ
- Shares are trading in the lower third of their 12-month price range of $3.27–$31.97.
- The 14-day relative strength index sits at a neutral 32.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- LENZ's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the LENZ conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for LENZ showed movement this week as the RSI zone transitioned from oversold to neutral. The stock remains in the healthcare sector with a valuation verdict currently awaiting full valuation.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for LENZ showed a shift this week as the RSI zone moved from neutral into oversold territory. The stock remains in the Healthcare sector with a valuation verdict of awaiting full valuation. This technical movement suggests increased downward momentum in the measure of price change relative to magnitude of price movement.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is LENZ stock undervalued?
TickrTrends has no fair-value estimate for LENZ yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is LENZ's TickrTrends verdict?
LENZ is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does LENZ compare to other Healthcare stocks?
LENZ ranks #190 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is LENZ overbought or oversold?
LENZ's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does LENZ pay a dividend?
LENZ has paid no dividend in the last twelve months; its last ex-dividend date on file was 2024-03-15.
When does LENZ report earnings next?
LENZ's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does LENZ usually beat earnings estimates?
Over its last 8 reported quarters LENZ beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LENZ?
Of 7 analysts covering LENZ, 5 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $23.9 (+630.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.